Page last updated: 2024-12-11

sk&f 93479

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SK&F 93479: inhibits nocturnal acid secretion [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6321389
CHEMBL ID3989758
MeSH IDM0103321

Synonyms (21)

Synonym
lupitidine hydrochloride [usan]
sk&f 93479
4(1h)-pyrimidinone, 2-((2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)amino)-5-((6-methyl-3-pyridinyl)methyl)-, trihydrochloride
2-((2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)amino)-5-((6-methyl-3-pyridyl)methyl)-4-(1h)-pyrimidinone trihydrochloride
sk&f-93479
skf-93479
lupitidine hydrochloride
2-({2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)thio]ethyl}amino)-5-[(6-methylpyridin-3-yl)methyl]pyrimidin-4(1h)-one trihydrochloride
lupitidine.3hcl
D04794
lupitidine hydrochloride (usan)
2-[2-[[5-(2-aminopropan-2-yl)furan-2-yl]methylsulfanyl]ethylamino]-5-[(6-methylpyridin-3-yl)methyl]-1h-pyrimidin-6-one trihydrochloride
unii-xku5yy749w
xku5yy749w ,
lupitidine hcl
2-[[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]amino]-5-[(6-methyl-3-pyridyl)methyl]-4-(1h)-pyrimidinone trihydrochloride
2-(2-(5-(dimethylaminomethyl)furan-2-ylmethylthio)-ethyl-amino)-5-(6-methylpyrid-3-ylmethyl)-pyrimidin-4-one trihydrochloride
DTXSID5020786
lupitidine trihydrochloride
CHEMBL3989758
2-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylamino]-5-[(6-methylpyridin-3-yl)methyl]-1h-pyrimidin-6-one;trihydrochloride

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effectiveness of the histamine H2-receptor antagonist, SKF 93479, in preventing gizzard ulcerations when given in combination with cysteamine-HCl was also examined."( Gizzard ulceration in chicks fed cysteamine alone or in combination with a histamine H2-receptor antagonist.
Hedde, RD; Lindsey, TO; Zavy, MT, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
" This was apparent after a single dose of the compound and was reversible after dosing for 7 days."( Effects of toxic doses of a novel histamine (H2) antagonist on the rat thyroid gland.
Atterwill, CK; Brown, CG; Harland, RF; Major, IR, 1987
)
0.27
" Investigative studies showed evidence for marked and sustained hypergastrinemia increasing on chronic dosing which was capable of restoring gastric acid secretion and pH to near control values."( Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
Betton, GR; Buckley, P; Dormer, CS; Pert, P; Price, CA; Wells, T, 1988
)
0.49
" Mean inhibitions of MAO during the 4th h after dosing of SK&F 93479 were significant at all dose levels, and a significant effect could still be seen during the 26th h for the two oral doses."( Repeated pentagastrin-stimulated gastric acid secretory tests carried out in the evaluation of the pharmacodynamics of a new histamine H2-receptor antagonist, SK&F 93479.
Bodemar, G; Jönsson, KA; Norlander, B; Walan, A, 1984
)
0.71
" Forestomach lesions of marked focal hyperplasia and hyperkeratosis were observed at a 48% incidence after 1 year daily gavage dosing with 1000 mg/kg."( Pathology of the forestomach in rats treated for 1 year with a new histamine H2-receptor antagonist, SK&F 93479 trihydrochloride.
Betton, GR; Salmon, GK, 1984
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (94.59)18.7374
1990's2 (5.41)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.53 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (7.89%)5.53%
Reviews1 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]